TDC
SGMO

Thompson Davis & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Thompson Davis & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4K Hold
250
– – 0.01% 606
2018
Q2 		$4K Hold
250
– – 0.01% 544
2018
Q1 		$5K Buy
+250
New +$5.34K 0.01% 488
2017
Q4 		– Sell
-1,500
Closed -$23K – 1022
2017
Q3 		$23K Buy
+1,500
New +$16.6K 0.04% 439
2017
Q2 		– Sell
-1,500
Closed -$8K – 1160
2017
Q1 		$8K Buy
+1,500
New +$6.02K 0.01% 768

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Thompson Davis & Co's SGMO Position: Q3 2018 in Review

Thompson Davis & Co held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q3 2018 at 250 shares worth $4K. The position accounts for 0.01% of the portfolio, ranked #606.

Thompson Davis & Co first reported a position in SGMO in Q1 2017 and has held it in 5 quarters since. The position peaked at $23K in Q3 2017. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

  • Thompson Davis & Co held 250 shares of SANGAMO THERAPEUTICS INC worth $4K as of Q3 2018.
  • Thompson Davis & Co left its SANGAMO THERAPEUTICS INC share count unchanged in Q3 2018.
  • SANGAMO THERAPEUTICS INC made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #606 holding.
  • Thompson Davis & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2017 and has held it in 5 quarters since.
  • Thompson Davis & Co's SANGAMO THERAPEUTICS INC position peaked at $23K in Q3 2017.
  • 217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.